New Hybrid Compounds Incorporating Natural Products as Multifunctional Agents against Alzheimer’s Disease
-
Published:2023-09-22
Issue:10
Volume:15
Page:2369
-
ISSN:1999-4923
-
Container-title:Pharmaceutics
-
language:en
-
Short-container-title:Pharmaceutics
Author:
Ciccone Lidia1ORCID, Camodeca Caterina1ORCID, Tonali Nicolò2ORCID, Barlettani Lucia1ORCID, Rossello Armando13, Fruchart Gaillard Carole4, Kaffy Julia2, Petrarolo Giovanni1ORCID, La Motta Concettina1ORCID, Nencetti Susanna1ORCID, Orlandini Elisabetta35
Affiliation:
1. Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy 2. CNRS, BioCIS, Bâtiment Henri Moissan, Université Paris-Saclay, 17 Av. des Sciences, 91400 Orsay, France 3. Research Center “E. Piaggio”, University of Pisa, 56122 Pisa, Italy 4. CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SIMoS, Université Paris Saclay, 91191 Gif-sur-Yvette, France 5. Department of Earth Sciences, University of Pisa, Via Santa Maria 53, 56126 Pisa, Italy
Abstract
A series of new hybrid derivatives 1a–c, 2a–c, 3a–c, 4a–c, 5a–c, inspired by nature, were synthesized and studied as multifunctional agents for the treatment of Alzheimer’s disease (AD). These compounds were designed to merge together the trifluoromethyl benzyloxyaminic bioactive moiety, previously identified, with different acids available in nature. The ability of the synthesized compounds to chelate biometals, such as Cu2+, Zn2+ and Fe2+, was studied by UV–Vis spectrometer, and through a preliminary screening their antioxidant activity was evaluated by DPPH. Then, selected compounds were tested by in vitro ABTS free radical method and ex vivo rat brain TBARS assay. Compounds 2a–c, combining the strongest antioxidant and biometal chelators activities, were studied for their ability to contrast Aβ1-40 fibrillization process. Finally, starting from the promising profile obtained for compound 2a, we evaluated if it could be able to induce a positive cross-interaction between transthyretin (TTR) and Aβ in presence and in absence of Cu2+.
Funder
Italian Ministry of Education, University, and Research
Subject
Pharmaceutical Science
Reference94 articles.
1. Alzheimer Disease;Knopman;Nat. Rev. Dis. Primers,2021 2. Aaseth, J., Skalny, A.V., Roos, P.M., Alexander, J., Aschner, M., and Tinkov, A.A. (2021). Copper, Iron, Selenium and Lipo-Glycemic Dysmetabolism in Alzheimer’s Disease. Int. J. Mol. Sci., 22. 3. Fasae, K.D., Abolaji, A.O., Faloye, T.R., Odunsi, A.Y., Oyetayo, B.O., Enya, J.I., Rotimi, J.A., Akinyemi, R.O., Whitworth, A.J., and Aschner, M. (2021). Metallobiology and Therapeutic Chelation of Biometals (Copper, Zinc and Iron) in Alzheimer’s Disease: Limitations, and Current and Future Perspectives. J. Trace Elem. Med. Biol., 67. 4. Arruda, M.A.Z. (2018). Metallomics: The Science of Biometals, Springer International Publishing. Advances in Experimental Medicine and Biology. 5. Effect of Metal Ions on Alzheimer’s Disease;Liu;Brain Behav.,2022
|
|